Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Int J Cancer. 2009 May 1;124(9):2148–2151. doi: 10.1002/ijc.24079

Table 1.

Baseline characteristics of participants in the Polyp Prevention Trial with genotype data by adenoma recurrence

Baseline Characteristic All subjects n=1723 No recurrence n=1050 Any recurrence n=673 Multiple recurrence n=286 Advanced recurrence n=109
Age (y) 61.0 ± 10.0 59.8 ± 10.2 62.9 ± 9.3* 64.8 ± 9.3* 65.6 ± 9.2*
Body Mass Index (kg/m2) 27.6 ± 3.9 27.5 ± 3.9 27.7 ± 3.9 27.9 ± 3.8* 28.0 ± 4.2
Gender (%)
Male 1,103 (64.2) 624 (59.6) 479 (71.4)* 215 (75.4)* 76 (69.7)
Female 615 (35.8) 423 (40.4) 192 (28.6) 70 (24.6) 33 (30.3)
Race (%)
White 1,540 (89.6) 938 (89.6) 602 (89.7) 264 (92.6) 98 (89.9)
African American 135 (7.9) 84 (8.0) 51 (7.6) 16 (5.6) 11 (10.1)
Other 43 (2.5) 25 (2.4) 18 (2.7) 5 (1.8) 0
Education (%)
< High school 425 (24.7) 252 (24.1) 173 (25.8) 79 (27.7) 29 (26.6)
> High school 1,293 (75.3) 795 (75.9) 498 (74.2) 206 (72.3) 80 (73.4)
Smoking status (%)
Never 683 (39.8) 428 (40.9) 255 (38.0) 111 (38.9) 42 (38.5)
Former 814 (47.4) 489 (46.7) 325 (48.4) 134 (47.0) 55 (50.5)
Current 221 (12.9) 130 (12.4) 91 (13.6) 40 (14.0) 12 (11.0)
Family history (%)
No 472 (27.5) 283 (27.0) 189 (28.2) 87 (30.5) 78 (71.6)
Yes 1,246 (72.5) 764 (73.0) 482 (71.8) 198 (69.5) 31 (28.4)
Regular NSAID use (%)
No 603 (50.8) 380 (48.7) 253 (54.1) 108 (56.3) 45 (58.4)
Yes 582 (49.2) 367 (51.3) 215 (45.9) 84 (43.7) 32 (41.6)

Results are presented as mean ± SD for continuous variables and as percentages for categorical variables. P values were determined by t tests and or χ2 tests, as appropriate.

*

Comparison group: no adenoma recurrence; P < 0.01.

Comparison group: no adenoma recurrence; P < 0.05.

Regular NSAID use includes current use of NSAIDs on a regular basis (>1 per month) reported at three or more yearly study visits. The reference group of no NSAID use includes individuals who reported no current use of NSAIDs on a regular basis (<1 per month) at all five study visits.